Shares of Vascular Biogenics VBLT dipped over 10% after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 60.00% over the past year to ($0.16), which missed the estimate of ($0.13).
Revenue of $126,000 less by 10.64% year over year, which beat the estimate of $110,000.
Guidance
Vascular Biogenics hasn't issued any earnings guidance for the time being.
Vascular Biogenics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Mar 19, 2020
Time: 01:00 AM ET
Webcast URL: https://edge.media-server.com/mmc/p/2ih7jg38
Technicals
Company's 52-week high was at $1.90
Company's 52-week low was at $0.90
Price action over last quarter: down 16.34%
Company Overview
Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.